Biomea Fusion Inc.
Clinical trials sponsored by Biomea Fusion Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New diabetes pill icovamenib enters Mid-Stage trial Results expected Mar 2027 (estimated)
- New diabetes pill shows promise for patients stuck on ozempic Results expected Jun 2027 (estimated)
-
New diabetes pill icovamenib enters Mid-Stage trial
Disease control OngoingThis Phase 2 trial tests whether a new drug called icovamenib can help people with type 2 diabetes who still have high blood sugar despite taking other medications. About 60 adults aged 18 to 70 will receive either icovamenib or a placebo daily for 12 weeks. The main goal is to s…
Phase 2 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New obesity drug BMF-650 enters first human safety trial
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called BMF-650 in 80 otherwise healthy adults who are overweight or obese. Participants receive either the drug or a placebo, and researchers monitor for side effects, vital signs, and how the drug moves throu…
Phase 1 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill targets leukemia in early human trial
Disease control OngoingThis early-stage trial is testing an experimental pill called BMF-500 in 35 adults with acute leukemia, especially those with a specific genetic mutation (FLT3). The main goals are to check the drug's safety, find the right dose, and see if it can help control the disease. Partic…
Phase 1 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC